{"id":66696,"date":"2026-05-29T14:39:08","date_gmt":"2026-05-29T06:39:08","guid":{"rendered":"https:\/\/flcube.com\/?p=66696"},"modified":"2026-05-29T14:39:09","modified_gmt":"2026-05-29T06:39:09","slug":"konruns-pharmaceutical-to-present-promising-phase-ii-kc1036-data-in-advanced-thymic-tumors-at-asco-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66696","title":{"rendered":"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Konruns Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/603590:SHA\">SHA: 603590<\/a>) announced plans to present results from a <strong>Phase II clinical study<\/strong> of its <strong>KC1036<\/strong> in patients with <strong>advanced thymic tumors<\/strong> progressing after prior platinum-based chemotherapy at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong>. KC1036 is a <strong>Category 1 chemical drug<\/strong> that demonstrates anti-tumor activity through inhibition of multiple targets, including <strong>VEGFR2 and AXL<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-study-design-amp-patient-population\" class=\"wp-block-heading\">Clinical Study Design &amp; Patient Population<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced thymic tumors post-platinum chemotherapy<\/td><\/tr><tr><td><strong>Total Enrolled<\/strong><\/td><td>31 patients<\/td><\/tr><tr><td><strong>Thymic Carcinoma (TC)<\/strong><\/td><td>25 patients<\/td><\/tr><tr><td><strong>Thymoma (T)<\/strong><\/td><td>6 patients<\/td><\/tr><tr><td><strong>Data Cutoff<\/strong><\/td><td>June 9, 2025<\/td><\/tr><tr><td><strong>Median Follow-up<\/strong><\/td><td>19.3 months<\/td><\/tr><tr><td><strong>Efficacy Evaluable<\/strong><\/td><td>All 31 patients<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-key-efficacy-results\" class=\"wp-block-heading\">Key Efficacy Results<\/h2>\n\n\n\n<h3 id=\"h-thymic-carcinoma-cohort-n-25\" class=\"wp-block-heading\">Thymic Carcinoma Cohort (n=25)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Overall Response Rate (ORR)<\/strong><\/td><td>20.0%<\/td><\/tr><tr><td><strong>Disease Control Rate (DCR)<\/strong><\/td><td>80%<\/td><\/tr><tr><td><strong>Median Progression-Free Survival (PFS)<\/strong><\/td><td>8.2 months<\/td><\/tr><tr><td><strong>Median Duration of Response (DoR)<\/strong><\/td><td>15.3 months<\/td><\/tr><tr><td><strong>18-month Overall Survival (OS) Rate<\/strong><\/td><td>75.5%<\/td><\/tr><tr><td><strong>Median OS<\/strong><\/td><td>Not yet reached<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-thymoma-cohort-n-6\" class=\"wp-block-heading\">Thymoma Cohort (n=6)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease Control Rate (DCR)<\/strong><\/td><td>100%<\/td><\/tr><tr><td><strong>Median Progression-Free Survival (PFS)<\/strong><\/td><td>13.6 months<\/td><\/tr><tr><td><strong>18-month Overall Survival (OS) Rate<\/strong><\/td><td>100%<\/td><\/tr><tr><td><strong>Median OS<\/strong><\/td><td>Not yet reached<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-development-status\" class=\"wp-block-heading\">Drug Profile &amp; Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Classification:<\/strong> Category 1 chemical drug (novel molecular entity)<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Multi-target inhibitor targeting VEGFR2 and AXL pathways<\/li>\n\n\n\n<li><strong>Current Indications in Development:<\/strong><\/li>\n\n\n\n<li>Gastrointestinal tumors<\/li>\n\n\n\n<li>Thymic tumors<\/li>\n\n\n\n<li>Pediatric Ewing sarcoma<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> No new safety signals observed, consistent with previously established profile<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-therapeutic-significance\" class=\"wp-block-heading\">Market Context &amp; Therapeutic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Medical Need:<\/strong> Thymic tumors represent rare but challenging malignancies with limited treatment options after platinum-based chemotherapy failure<\/li>\n\n\n\n<li><strong>Clinical Differentiation:<\/strong> KC1036 demonstrates meaningful disease control and survival outcomes in a heavily pre-treated population<\/li>\n\n\n\n<li><strong>ASCO Platform:<\/strong> Presentation at premier oncology conference provides global visibility and scientific validation<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> Multi-indication approach maximizes asset value across different tumor types<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-for-thymic-tumors\" class=\"wp-block-heading\">Competitive Landscape for Thymic Tumors<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Approach<\/th><th>Current Options<\/th><th>KC1036 Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Second-line Chemotherapy<\/strong><\/td><td>Limited efficacy, significant toxicity<\/td><td>Targeted approach with manageable safety<\/td><\/tr><tr><td><strong>Immunotherapy<\/strong><\/td><td>Modest response rates in thymic carcinoma<\/td><td>Higher DCR (80%) in TC cohort<\/td><\/tr><tr><td><strong>Anti-angiogenic Agents<\/strong><\/td><td>Limited data in thymic tumors<\/td><td>Dual targeting of VEGFR2 and AXL pathways<\/td><\/tr><tr><td><strong>Clinical Evidence<\/strong><\/td><td>Sparse Phase II data available<\/td><td>Robust dataset with mature follow-up (19.3 months)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for KC1036. Actual results may differ due to risks including final ASCO presentation data, regulatory decisions, and competitive dynamics in the oncology landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603590_20260529_JTC9.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603590_20260529_JTC9.\"><\/object><a id=\"wp-block-file--media-526e0970-3acd-4e23-89df-d278bf75aff6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603590_20260529_JTC9.pdf\">603590_20260529_JTC9<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/603590_20260529_JTC9.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-526e0970-3acd-4e23-89df-d278bf75aff6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,16,17,2984,1532],"class_list":["post-66696","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-cancer","tag-clinical-trial-results","tag-konruns-pharmaceutical","tag-sha-603590"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II clinical study of its KC1036 in patients with advanced thymic tumors progressing after prior platinum-based chemotherapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. KC1036 is a Category 1 chemical drug that demonstrates anti-tumor activity through inhibition of multiple targets, including VEGFR2 and AXL.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66696\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II clinical study of its KC1036 in patients with advanced thymic tumors progressing after prior platinum-based chemotherapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. KC1036 is a Category 1 chemical drug that demonstrates anti-tumor activity through inhibition of multiple targets, including VEGFR2 and AXL.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66696\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T06:39:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T06:39:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66696#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66696\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026\",\"datePublished\":\"2026-05-29T06:39:08+00:00\",\"dateModified\":\"2026-05-29T06:39:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66696\"},\"wordCount\":388,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Cancer\",\"Clinical trial results\",\"Konruns Pharmaceutical\",\"SHA: 603590\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66696#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66696\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66696\",\"name\":\"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T06:39:08+00:00\",\"dateModified\":\"2026-05-29T06:39:09+00:00\",\"description\":\"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II clinical study of its KC1036 in patients with advanced thymic tumors progressing after prior platinum-based chemotherapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. KC1036 is a Category 1 chemical drug that demonstrates anti-tumor activity through inhibition of multiple targets, including VEGFR2 and AXL.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66696#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66696\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66696#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II clinical study of its KC1036 in patients with advanced thymic tumors progressing after prior platinum-based chemotherapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. KC1036 is a Category 1 chemical drug that demonstrates anti-tumor activity through inhibition of multiple targets, including VEGFR2 and AXL.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66696","og_locale":"en_US","og_type":"article","og_title":"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026","og_description":"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II clinical study of its KC1036 in patients with advanced thymic tumors progressing after prior platinum-based chemotherapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. KC1036 is a Category 1 chemical drug that demonstrates anti-tumor activity through inhibition of multiple targets, including VEGFR2 and AXL.","og_url":"https:\/\/flcube.com\/?p=66696","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T06:39:08+00:00","article_modified_time":"2026-05-29T06:39:09+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66696#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66696"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026","datePublished":"2026-05-29T06:39:08+00:00","dateModified":"2026-05-29T06:39:09+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66696"},"wordCount":388,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Cancer","Clinical trial results","Konruns Pharmaceutical","SHA: 603590"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66696#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66696","url":"https:\/\/flcube.com\/?p=66696","name":"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T06:39:08+00:00","dateModified":"2026-05-29T06:39:09+00:00","description":"Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced plans to present results from a Phase II clinical study of its KC1036 in patients with advanced thymic tumors progressing after prior platinum-based chemotherapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. KC1036 is a Category 1 chemical drug that demonstrates anti-tumor activity through inhibition of multiple targets, including VEGFR2 and AXL.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66696#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66696"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66696#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Konruns Pharmaceutical to Present Promising Phase II KC1036 Data in Advanced Thymic Tumors at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66696"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66696\/revisions"}],"predecessor-version":[{"id":66699,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66696\/revisions\/66699"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}